Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Daneshgah St, Tabriz, 51666-14766, Iran.
Department of Physiology, Ardabil Branch, Islamic Azad University, Ardabil, Iran.
Stem Cell Res Ther. 2020 Sep 15;11(1):400. doi: 10.1186/s13287-020-01921-2.
Asthma is a chronic inflammatory disease associated with airway hyper-responsiveness, chronic inflammatory response, and excessive structural remodeling. The current therapeutic strategies in asthmatic patients are based on controlling the activity of type 2 T helper lymphocytes in the pulmonary tissue. However, most of the available therapies are symptomatic and expensive and with diverse side outcomes in which the interruption of these modalities contributes to the relapse of asthmatic symptoms. Up to date, different reports highlighted the advantages and beneficial outcomes regarding the transplantation of different stem cell sources, and relevant products from for the diseases' alleviation and restoration of injured sites. However, efforts to better understand by which these cells elicit therapeutic effects are already underway. The precise understanding of these mechanisms will help us to translate stem cells into the clinical setting. In this review article, we described current knowledge and future perspectives related to the therapeutic application of stem cell-based therapy in animal models of asthma, with emphasis on the underlying therapeutic mechanisms.
哮喘是一种慢性炎症性疾病,与气道高反应性、慢性炎症反应和过度的结构重塑有关。目前哮喘患者的治疗策略基于控制肺部组织中 2 型 T 辅助淋巴细胞的活性。然而,大多数可用的治疗方法都是对症的,而且费用昂贵,并且具有不同的副作用,其中这些方法的中断会导致哮喘症状的复发。迄今为止,不同的报告强调了不同干细胞来源的移植以及相关产品在缓解疾病和修复受损部位方面的优势和有益结果。然而,人们已经在努力更好地了解这些细胞是如何产生治疗效果的。精确理解这些机制将有助于我们将干细胞转化为临床应用。在这篇综述文章中,我们描述了与哮喘动物模型中基于干细胞的治疗的治疗应用相关的当前知识和未来展望,重点介绍了潜在的治疗机制。